- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about SRPT
Recent news which mentions SRPT
Earnings Scheduled For February 26, 2025
February 26, 2025
From Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 14, 2025
From Benzinga
2 Growth Stocks to Buy Hand Over Fist in February
February 09, 2025
From Motley Fool
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
January 27, 2025
From Benzinga
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics
January 15, 2025
Tickers
SRPT
From Benzinga
From Benzinga
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
December 13, 2024
From Benzinga
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
December 01, 2024
From Benzinga
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
December 01, 2024
From Benzinga
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
November 26, 2024
From Benzinga
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
November 26, 2024
From Benzinga
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
November 25, 2024
From Benzinga
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
November 07, 2024
From Benzinga
From Benzinga
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript
November 07, 2024
Tickers
SRPT
From Motley Fool
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
October 21, 2024
From Benzinga
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
October 18, 2024
From Benzinga
2 High-Flying Growth Stocks With Massive Upside Potential
October 17, 2024
From Motley Fool
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
October 03, 2024
From Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
September 18, 2024
From Benzinga
These 2 Biotech Stocks Are Set to Soar
September 13, 2024
From Motley Fool
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
September 03, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.